vs

Side-by-side financial comparison of GigaCloud Technology Inc (GCT) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.

GigaCloud Technology Inc is the larger business by last-quarter revenue ($332.6M vs $281.3M, roughly 1.2× Guardant Health, Inc.). GigaCloud Technology Inc runs the higher net margin — 11.2% vs -45.7%, a 56.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.7%). GigaCloud Technology Inc produced more free cash flow last quarter ($77.1M vs $-54.2M). Over the past eight quarters, GigaCloud Technology Inc's revenue compounded faster (36.6% CAGR vs 29.2%).

GigaCloud Technology Inc. is an American e-commerce company that helps retailers buy and sell big and bulky, non-standardized items such as furniture, appliances, and fitness equipment. They own a business-to-business online marketplace and act as a middleman by handling sales, logistics and also delivery to end customers. GigaCloud is headquartered in El Monte, California, and is listed on the Nasdaq stock exchange since August 2022.

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.

GCT vs GH — Head-to-Head

Bigger by revenue
GCT
GCT
1.2× larger
GCT
$332.6M
$281.3M
GH
Growing faster (revenue YoY)
GH
GH
+29.7% gap
GH
39.4%
9.7%
GCT
Higher net margin
GCT
GCT
56.9% more per $
GCT
11.2%
-45.7%
GH
More free cash flow
GCT
GCT
$131.3M more FCF
GCT
$77.1M
$-54.2M
GH
Faster 2-yr revenue CAGR
GCT
GCT
Annualised
GCT
36.6%
29.2%
GH

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GCT
GCT
GH
GH
Revenue
$332.6M
$281.3M
Net Profit
$37.2M
$-128.5M
Gross Margin
23.2%
64.6%
Operating Margin
12.2%
-43.0%
Net Margin
11.2%
-45.7%
Revenue YoY
9.7%
39.4%
Net Profit YoY
-8.6%
-15.8%
EPS (diluted)
$0.99
$-1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GCT
GCT
GH
GH
Q4 25
$281.3M
Q3 25
$332.6M
$265.2M
Q2 25
$322.6M
$232.1M
Q1 25
$271.9M
$203.5M
Q4 24
$295.8M
$201.8M
Q3 24
$303.3M
$191.5M
Q2 24
$310.9M
$177.2M
Q1 24
$251.1M
$168.5M
Net Profit
GCT
GCT
GH
GH
Q4 25
$-128.5M
Q3 25
$37.2M
$-92.7M
Q2 25
$34.6M
$-99.9M
Q1 25
$27.1M
$-95.2M
Q4 24
$31.0M
$-111.0M
Q3 24
$40.7M
$-107.8M
Q2 24
$27.0M
$-102.6M
Q1 24
$27.2M
$-115.0M
Gross Margin
GCT
GCT
GH
GH
Q4 25
64.6%
Q3 25
23.2%
64.7%
Q2 25
23.9%
65.0%
Q1 25
23.4%
63.3%
Q4 24
22.0%
61.6%
Q3 24
25.5%
61.1%
Q2 24
24.6%
59.1%
Q1 24
26.5%
61.2%
Operating Margin
GCT
GCT
GH
GH
Q4 25
-43.0%
Q3 25
12.2%
-37.3%
Q2 25
11.1%
-45.9%
Q1 25
10.4%
-54.6%
Q4 24
9.3%
-62.4%
Q3 24
13.4%
-61.3%
Q2 24
8.8%
-56.8%
Q1 24
13.9%
-59.2%
Net Margin
GCT
GCT
GH
GH
Q4 25
-45.7%
Q3 25
11.2%
-35.0%
Q2 25
10.7%
-43.0%
Q1 25
10.0%
-46.8%
Q4 24
10.5%
-55.0%
Q3 24
13.4%
-56.3%
Q2 24
8.7%
-57.9%
Q1 24
10.8%
-68.2%
EPS (diluted)
GCT
GCT
GH
GH
Q4 25
$-1.01
Q3 25
$0.99
$-0.74
Q2 25
$0.91
$-0.80
Q1 25
$0.68
$-0.77
Q4 24
$0.76
$-0.90
Q3 24
$0.98
$-0.88
Q2 24
$0.65
$-0.84
Q1 24
$0.66
$-0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GCT
GCT
GH
GH
Cash + ST InvestmentsLiquidity on hand
$365.9M
$378.2M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$457.3M
$-99.3M
Total Assets
$1.1B
$2.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GCT
GCT
GH
GH
Q4 25
$378.2M
Q3 25
$365.9M
$580.0M
Q2 25
$303.0M
$629.1M
Q1 25
$286.8M
$698.6M
Q4 24
$302.4M
$525.5M
Q3 24
$259.8M
$585.0M
Q2 24
$207.8M
$933.7M
Q1 24
$195.3M
$1.0B
Total Debt
GCT
GCT
GH
GH
Q4 25
$1.5B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
GCT
GCT
GH
GH
Q4 25
$-99.3M
Q3 25
$457.3M
$-354.5M
Q2 25
$431.4M
$-305.5M
Q1 25
$412.9M
$-250.8M
Q4 24
$405.2M
$-139.6M
Q3 24
$400.4M
$-60.1M
Q2 24
$358.4M
$-1.6M
Q1 24
$317.8M
$68.3M
Total Assets
GCT
GCT
GH
GH
Q4 25
$2.0B
Q3 25
$1.1B
$1.3B
Q2 25
$1.1B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.1B
$1.5B
Q3 24
$1.1B
$1.5B
Q2 24
$1.1B
$1.6B
Q1 24
$977.6M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GCT
GCT
GH
GH
Operating Cash FlowLast quarter
$78.3M
$-26.4M
Free Cash FlowOCF − Capex
$77.1M
$-54.2M
FCF MarginFCF / Revenue
23.2%
-19.3%
Capex IntensityCapex / Revenue
0.4%
9.9%
Cash ConversionOCF / Net Profit
2.10×
TTM Free Cash FlowTrailing 4 quarters
$188.1M
$-233.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GCT
GCT
GH
GH
Q4 25
$-26.4M
Q3 25
$78.3M
$-35.4M
Q2 25
$38.6M
$-60.3M
Q1 25
$9.4M
$-62.7M
Q4 24
$68.4M
$-64.5M
Q3 24
$55.2M
$-51.1M
Q2 24
$19.1M
$-94.0M
Q1 24
$15.3M
$-30.3M
Free Cash Flow
GCT
GCT
GH
GH
Q4 25
$-54.2M
Q3 25
$77.1M
$-45.8M
Q2 25
$37.0M
$-65.9M
Q1 25
$7.0M
$-67.1M
Q4 24
$66.9M
$-83.4M
Q3 24
$51.4M
$-55.3M
Q2 24
$12.9M
$-99.1M
Q1 24
$11.3M
$-37.2M
FCF Margin
GCT
GCT
GH
GH
Q4 25
-19.3%
Q3 25
23.2%
-17.3%
Q2 25
11.5%
-28.4%
Q1 25
2.6%
-33.0%
Q4 24
22.6%
-41.3%
Q3 24
16.9%
-28.9%
Q2 24
4.2%
-55.9%
Q1 24
4.5%
-22.1%
Capex Intensity
GCT
GCT
GH
GH
Q4 25
9.9%
Q3 25
0.4%
3.9%
Q2 25
0.5%
2.4%
Q1 25
0.9%
2.2%
Q4 24
0.5%
9.4%
Q3 24
1.3%
2.2%
Q2 24
2.0%
2.9%
Q1 24
1.6%
4.1%
Cash Conversion
GCT
GCT
GH
GH
Q4 25
Q3 25
2.10×
Q2 25
1.12×
Q1 25
0.35×
Q4 24
2.21×
Q3 24
1.36×
Q2 24
0.71×
Q1 24
0.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GCT
GCT

Services$108.4M33%
Transferred Over Time$89.8M27%
Product Sales To B$50.1M15%
Last Mile Delivery Service$49.2M15%
Warehousing Service$14.2M4%
Ocean Transportation Service$9.0M3%
Platform Commission$4.9M1%
Drayage Service$3.2M1%

GH
GH

Oncology$189.9M68%
Biopharma Data$54.0M19%
Screening$35.1M12%
Licensing Other$2.2M1%

Related Comparisons